You are in: eMedicine Specialties > Infectious Diseases > MEDICAL TOPICS Streptococcus Group B InfectionsArticle Last Updated: Mar 24, 2006AUTHOR AND EDITOR INFORMATIONAuthor: Sharat K Narayanan, MD, Consulting Staff, Department of Internal Medicine, Stone Mountain Health Services, Haysi Clinic Coauthor(s): Charles S Levy, MD, Associate Professor, Department of Medicine, Section of Infectious Disease, George Washington University School of Medicine Editors: Pranatharthi Haran Chandrasekar, MD, Director of Infectious Disease Fellowship, Professor, Department of Internal Medicine, Harper Hospital, Wayne State University School of Medicine; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; John L Brusch, MD, FACP, Assistant Professor of Medicine, Harvard Medical School; Consulting Staff, Department of Medicine and Infectious Disease Service, Cambridge Health Alliance; Eleftherios Mylonakis, MD, Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital; Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital Author and Editor Disclosure Synonyms and related keywords: Streptococcus agalactiae, S agalactiae, group B streptococci, group B Streptococcus, group B streptococcal disease, streptococcal disease, coccus, cocci, group B bacteremia, bacteremia, bacterial pneumonia, group B streptococcal infection INTRODUCTIONBackgroundLancefield group B beta streptococci, Streptococcus agalactiae, once were considered pathogens only of domestic animals, causing mastitis in cows. S agalactiae now is best known as a cause of postpartum infection and as the most common cause of neonatal sepsis. More recently, the role of this organism as a cause of infection in nonpregnant adults has been described in a number of series. These studies allow description of the clinical spectrum of disease, including clinical features, risk factors, therapy, and outcome of group B streptococci in the nonpregnant adult. Group B streptococci colonize the vaginal and gastrointestinal tract in healthy women. Neonates acquire the organism as a result of vertical transmission from the maternal genital tract to the infant in utero or at delivery. Carriage rates in women can range from 5-40%. While acquisition of the organism by the neonate is efficient, the rate of subsequent clinical disease is quite low, 1-2%. Neonatal sepsis from group B streptococci is a rare event, but it is more common in the setting of prematurity and prolonged rupture of the membranes. The large number of women who carry this organism and the fact that neonatal sepsis is a rare event make a prevention approach to this problem difficult. Many pregnant women require treatment to prevent a single neonatal infection. This problem has been studied, focusing on both immunoprophylaxis and chemoprophylaxis. Disease in the neonate is divided into early and late disease. Early neonatal sepsis with group B streptococci often is observed within 24 hours of delivery, but it can become apparent as late as 7 days after birth. Nothing specific regarding the clinical presentation in early disease differentiates group B streptococci as the etiology from other pathogens. Pneumonia with bacteremia is common and meningitis less likely. Late disease is defined as infection after 1 week and before 3 months after birth. Late disease commonly is serotype III, characterized by bacteremia and meningitis. Group B streptococcal infection in the infant is more common in the absence of antibody to group B streptococci. Because antibody to group B streptococci is protective for the disease in the animal model, interest in vaccination as an approach to reduce the incidence of group B streptococcal colonization in healthy women is ongoing. Vaccine development was promising at one time, but shifting serotypes of group B streptococci responsible for clinical disease have limited this approach. Problems related to access to vaccination for women of childbearing age and the emotion and possible litigation associated with vaccination during pregnancy have made this approach less attractive. The current approach to the prevention of group B streptococcal infection in pregnancy has become a national standard as a result of the effort of the Centers for Disease Control and Prevention (CDC) in 1995. This approach requires intrapartum antimicrobial prophylaxis in term women with culture evidence of recent vaginal or rectal group B streptococcal infection. Women without a known group B streptococci status delivering before 37 weeks' gestation with premature rupture of the membranes or intrapartum fever also are candidates for intrapartum antimicrobial prophylaxis. Penicillin or ampicillin is the initial approach to this problem. Clindamycin and erythromycin are standard for the individual with penicillin allergy, but group B streptococci now are not always sensitive to these 2 drugs. Group B streptococci as a cause of infection in pregnant women can be manifest by chorioamnionitis, endometritis, or genitourinary infection with bacteremia. Rarely, endocarditis or meningitis can be observed. Only in the last 3 decades has the role of group B streptococci as a serious pathogen in the nonpregnant adult been well defined. A number of studies have allowed description of the clinical spectrum of disease, including clinical features, risk factors, therapy, and outcomes. This organism is an extremely rare cause of infection in a healthy individual. It almost always is associated with underlying abnormalities. Diabetes is associated most commonly with group B streptococci in some series. This association, which the authors have observed over the last 25 years, is unexplained. Malignancy was the most common association in a series from an institution with a large oncology population. Cardiovascular and genitourinary abnormalities have been observed as major factors for the acquisition of group B streptococci. Other conditions associated with group B streptococci in adults include neurologic deficits, cirrhosis, steroids, AIDS, renal dysfunction, and peripheral vascular disease. Group B streptococci in elderly people, aged 70 years or older, is strongly linked to congestive heart failure and being bedridden. Urinary tract infection, pneumonia, and soft tissue infection were the most common illnesses in this group. Neurologic illness is associated with pneumonia in elderly people, possibly as a result of aspiration of group B streptococci from the upper respiratory tract. Nosocomial infection with group B streptococci was common in this group and is described in other series. The source of this infection is not always clear, but the genitourinary tract and skin are thought to be the sources of some nosocomial infections. Group B streptococci colonize not only the female genital tract but also are found commonly in the gastrointestinal tract and have been described as asymptomatic colonizers of the urethra in both men and women. Group B streptococci can colonize the upper respiratory tract. Colonization also is observed in wound and soft tissue cultures in the absence of obvious infection. Determining the acquisition and transmission of the organism can be puzzling. Group B streptococci are very invasive but produce little inflammation at the entry site. Primary bacteremia without an obvious source with group B streptococcal infection is a common presentation in adults. While one series suggests that group B streptococci bacteremia is low grade and easily controlled with little morbidity, other authors suggest that the clinical presentation may be that of classic sepsis with shock and may carry a high mortality. Sustained bacteremia raises the question of endocarditis or an infected catheter. Group B streptococci can be a cause of acute destructive endocarditis, which may require emergency valve replacement. Other sources of bacteremia include pneumonia in elderly people and genitourinary and soft tissue infection. Polymicrobial bacteremia with group B streptococci is observed in disease related to infected lines and also can reflect a genitourinary source. Urinary tract infections are a common manifestation of group B streptococcal disease. This is observed in pregnancy as well as in the nonpregnant adult. A variety of skin and soft tissue infections, including cellulitis, line-site infection, infected decubiti, diabetic feet, osteomyelitis, and arthritis, are described commonly and are the most common group B streptococcal infections in some reports. Necrotizing fasciitis caused by group B streptococci has been described recently. The soft tissue and bone infections may not be cured by a medical therapy alone, and surgical intervention may be necessary. For fasciitis or its possibility, surgery should be immediate. Other manifestations of group B streptococcal infection include meningitis, peritonitis, and endo-ophthalmitis. Group B streptococci at one time were sensitive to penicillin, ampicillin, cefazolin, erythromycin, and clindamycin. The organism remains sensitive to penicillin and ampicillin. While penicillin is the treatment of choice, that penicillin therapy produces a better outcome than other antibiotics is not clear. Because aminoglycoside may provide synergy in killing the organism, it often is added for serious infection. This 2-drug therapy is synergistic only if the organism is sensitive to aminoglycoside, making sensitivity testing important. Clinically, 2-drug therapy with penicillin and aminoglycoside has not been shown to improve the outcome over penicillin alone. The efficacy of clindamycin and macrolides is good, but sensitivity testing must be performed before using these antibiotics because resistance is observed and appears to be increasing. Group B streptococci always are sensitive to vancomycin, and it would be the treatment of choice in the penicillin-allergic patient. Quinolones may have efficacy for group B streptococci, but little clinical experience exists. Linezolid may play a role in treating this infection, but, in the literature, no experience with treating group B streptococcal infection with linezolid exists. PathophysiologyS agalactiae is a gram-positive coccus that, when cultured on sheep blood agar, forms glistening gray-white colonies with a narrow zone of beta hemolysis. It is an invasive encapsulated organism capable of producing severe disease in hosts who are immunocompromised. Infection in the absence of associated comorbid medical conditions is rare. Virulence is related to the polysaccharide toxin produced by group B streptococci. Immunity is mediated by antibody to the capsular polysaccharide and is serotype-specific. Several serotypes are known—Ia, Ib, Ic, II, III, IV, V, VI, VII, and VIII. Group B streptococci colonize the vagina, gastrointestinal tract, and the upper respiratory tract of healthy humans. The portal of entry is not apparent, but possible areas include the skin, genital tract, urinary tract, and respiratory tract. FrequencyUnited StatesGroup B streptococci are observed in neonatal sepsis in 1.8-3.2 out of 1000 live births. Early disease is observed in 1.4 out of 1000 births, while late disease is observed in 0.3 out of 1000 births. The incidence of early disease has decreased over the past decade, possibly as a result of the CDC guidelines for the prevention of neonatal colonization with group B streptococcus. The incidence of invasive group B streptococcal infections in the nonpregnant adult population of Atlanta during the period of 1982-1983 was 2.4 cases per 100,000 population. A subsequent study conducted in Atlanta from 1989-1990 revealed an incidence rate of 4.4 cases per 100,000 population. The incidence in adults older than 60 years rises to 18 cases per 100,000 population. This is similar to the incidence of pneumococcal sepsis. InternationalThe role of group B streptococci in the developing world is not well defined. Carriage rates and serotypes in women in less developed countries are similar to those observed in the industrial world. However, group B streptococci early disease in infants is not documented in less developed countries. A clear explanation for this has not been found. Mortality/MorbidityGroup B streptococci has significant mortality in both neonates and adults. The mortality rate of group B streptococci bacteremia ranges from 9-47% in adults. The mortality rate is highest for elderly patients with comorbid medical conditions. The highest mortality rate is observed in patients with endocarditis, meningitis, and pneumonia. The high mortality rate in elderly people with group B streptococci may not reflect the organism but may reflect the predisposing condition or conditions that put the individual at risk for group B streptococcal infection. The mortality rate of group B streptococcal infection in neonates is much less than that of nonpregnant adults. Increasing awareness of group B streptococcal infection in infants has led to improved outcome in recent years. Postpartum group B streptococcal infection is associated with a low mortality rate because the group at risk is comprised of healthy, young or middle-aged women. RaceThe incidence of group B streptococcal infection is higher in African Americans than whites. The difference is even more striking in older African Americans. These differences probably are a result of socioeconomic differences rather than race. Sex
Age
CLINICALHistoryOther than in cases of group B streptococcal infection in young and middle-aged women, a case of a healthy adult who develops group B streptococcal infection is extremely unusual. This infection almost always is associated with underlying abnormalities. Diabetes is the disease most commonly associated with group B streptococci in some series. This association, which the authors have observed over the last 25 years, is unexplained. Malignancy was the most common association in a series from an institution with a large oncology population. Cardiovascular and genitourinary abnormalities have been observed as major factors for the acquisition of group B streptococci. Other conditions associated with group B streptococcal infection in adults include neurologic deficits, cirrhosis, steroids, AIDS, renal dysfunction, and peripheral vascular disease. In elderly people aged 70 years or older, group B streptococcal infection is strongly linked to congestive heart failure and being bedridden. Pneumonia from group B streptococcal infection is rare and has few unique features. It is observed in elderly people with diabetes and with neurologic deficits. It may be the result of aspiration of group B streptococci that colonize the upper airway. In one series, it appeared to be associated with a high rate of bacteremia. Meningitis, a common manifestation of neonatal infection, is uncommon in adults. It almost always is associated with anatomical abnormalities contiguous with, or of, the central nervous system, usually as a result of neurosurgery. Bacteremia with group B streptococci is a common manifestation of this organism. While a genitourinary, soft tissue, or line-related source of infection is a possibility, in most cases, no source of infection can be identified. Group B streptococcal pneumonia in elderly people has been associated with bacteremia. Group B streptococcal bacteremia without a source always raises the possibility of endocarditis. Often, the diagnosis will become obvious because endocarditis with this organism is very destructive and frequently requires valve replacement for valve insufficiency. Skin and soft tissue infection, osteomyelitis, arthritis, discitis, and colonization of diabetic feet and decubitus ulcers are observed with group B streptococcal infection. Many of these patients are diabetic. The cause of this strong association is not clear. While medical therapy should cure many group B streptococcal infections, those involving skin, soft tissue, and bone may not be cured with antibiotics alone and may require surgical intervention. Chorioamnionitis, endometritis, and the full spectrum of urinary tract infection (from asymptomatic bacteruria to cystitis and pyelonephritis with bacteremia) are observed with group B streptococcal infection. These are common complications in young and middle-aged women that often are related to childbirth. Urinary tract infections with group B streptococci also are observed in elderly men and women. These individuals often have diabetes or genitourinary abnormalities.
Physical
DIFFERENTIALSEndometritis Meningitis Pneumonia, Bacterial Urinary Tract Infection, Females Urinary Tract Infections in Pregnancy Wound Infection
|
| Drug Name | Penicillin G (Pfizerpen) |
|---|---|
| Description | Interferes with synthesis of cell wall mucopeptide during active multiplication, resulting in bactericidal activity against susceptible microorganisms. Penicillin remains the drug of choice for group B streptococcal infection. |
| Adult Dose | 12-24 million U/d IV for 4 wk for endocarditis and osteomyelitis; 2-4 wk for bacteremia, pneumonia, and soft tissue infection |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration of tetracyclines can decrease effects of penicillin |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Caution in impaired renal function |
| Drug Name | Cefazolin (Ancef, Kefzol, Zolicef) |
|---|---|
| Description | First-generation semisynthetic cephalosporin that arrests bacterial cell wall synthesis, inhibiting bacterial growth. Primarily active against skin flora, including Staphylococcus aureus. Typically used alone for skin and skin structure coverage. IV and IM dosing regimens are similar. Cefazolin is alternative therapy to penicillin for group B streptococcal infection. Cefazolin would not be effective for meningitis. |
| Adult Dose | 1 g IV q8h |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with aminoglycosides may increase renal toxicity; may yield false-positive results on urine-dip test for glucose |
| Pregnancy | A - Safe in pregnancy |
| Precautions | Adjust dose in renal impairment; superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy |
| Drug Name | Vancomycin (Vancocin) |
|---|---|
| Description | Potent antibiotic directed against gram-positive organisms. Useful in the treatment of septicemia and skin structure infections. Indicated for patients who cannot receive or who have failed to respond to penicillins and cephalosporins or who have infections with resistant staphylococci. To avoid toxicity, the current recommendation is to assay vancomycin trough levels after the third dose drawn 0.5 h prior to next dosing. Use creatinine clearance to adjust dose in patients diagnosed with renal impairment. May need to adjust dose in renal impairment. Vancomycin is the initial treatment of choice for group B streptococcal infection in the penicillin-allergic individual. |
| Adult Dose | 1 g IV q12h |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Erythema, histaminelike flushing, and anaphylactic reactions may occur when administered with anesthetic agents; when taken concurrently with aminoglycosides, risk of nephrotoxicity may increase above that with aminoglycoside monotherapy; effects in neuromuscular blockade may be enhanced when coadministered with nondepolarizing muscle relaxants |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Caution in renal failure; red man syndrome is caused by too rapid IV infusion (dose administered over a few min), but it rarely happens when dose is administered as 2-h administration or as PO or IP administration; red man syndrome is not an allergic reaction |
| Drug Name | Gentamicin (Gentacidin, Garamycin) |
|---|---|
| Description | Aminoglycosides show synergy when used with penicillin for group B streptococcus. In neonates, the ill patient with sepsis and in certain situations, such as endocarditis, adding an aminoglycoside as a second drug may be helpful. The possible benefit must be weighed against the toxicity of renal and eighth nerve dysfunction, particularly in elderly people. The benefit of 2-drug therapy for group B streptococci has not been proven in terms of a better clinical outcome compared to penicillin therapy alone. The aminoglycoside needs to be tested against the isolate because only sensitive isolates can provide synergy. |
| Adult Dose | 60 mg IV q8h |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; non–dialysis-dependent renal insufficiency; preexisting eighth nerve dysfunction |
| Interactions | Coadministration with other aminoglycosides, cephalosporins, penicillins, and amphotericin B may increase nephrotoxicity; aminoglycosides enhance effects of neuromuscular blocking agents, thus prolonged respiratory depression may occur; coadministration with loop diuretics may increase the auditory toxicity of aminoglycosides; possible irreversible hearing loss of varying degrees may occur (monitor regularly) |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Narrow therapeutic index (not intended for long-term therapy); caution in renal failure (not on dialysis), myasthenia gravis, hypocalcemia, and conditions that depress neuromuscular transmission; adjust dose in renal impairment |
| Drug Name | Clindamycin (Cleocin) |
|---|---|
| Description | Not for use as initial therapy because a small percent of group B streptococci will be resistant to clindamycin. Should not be used for endocarditis, bacteremia, or meningitis. If bacteria are sensitive, it can be used for pneumonia, osteomyelitis, and soft tissue infection. May also be useful as oral therapy to follow a course of parenteral therapy or if access becomes an issue. |
| Adult Dose | 600 mg IV q6h; 900 mg IV q8h 300 mg PO q6h |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; regional enteritis; ulcerative colitis; hepatic impairment; antibiotic-associated colitis |
| Interactions | Increases duration of neuromuscular blockade induced by tubocurarine and pancuronium; erythromycin may antagonize effects of clindamycin; antidiarrheals may delay absorption of clindamycin |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis |
The authors and editors of eMedicine gratefully acknowledge the contributions of previous coauthor Mohamad Ossiani, MD, to the development and writing of this article.
Streptococcus Group B Infections excerpt
Article Last Updated: Mar 24, 2006